Zoetis

ZTS · NYSE

$80.04+$0.45 (+0.57%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $79.59

Latest news

Press releaseOct 20, 4:42 PM ETBusiness Wire
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
Press releaseOct 13, 7:30 AM ETBusiness Wire
Zoetis Appoints Iris Knobloch to its Board of Directors
Press releaseOct 8, 4:15 PM ETBusiness Wire
Zoetis Declares Fourth Quarter 2026 Dividend
Press releaseOct 6, 7:30 AM ETBusiness Wire
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
NewsOct 6, 6:53 AM ET
Zoetis Reports Q2 2026 Results: Full Earnings Call Transcript
Press releaseSep 24, 7:30 AM ETBusiness Wire
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
Press releaseSep 2, 7:30 AM ETBusiness Wire
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Press releaseAug 13, 3:51 PM ETBusiness Wire
Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
NewsAug 13, 1:09 PM ET
FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies
NewsAug 10, 5:33 AM ETAvi Kapoor
5 Stock Picks Last Week From Wall Street's Most Accurate Analysts
NewsAug 6, 2:10 PM ETVandana Singh
Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds
NewsAug 6, 7:00 AM ET
Zoetis Q2 Adj. EPS $1.87 Beats $1.86 Estimate, Sales $2.468B Miss $2.502B Estimate
Press releaseAug 6, 7:00 AM ETBusiness Wire
Zoetis Announces Second Quarter 2026 Results
Press releaseAug 6, 7:00 AM ETBusiness Wire
Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer
NewsJul 31, 9:19 AM ETRishabh Mishra
Michael Burry Expands Bets Against Nvidia, Micron— and Is Now Buying Lululemon and DraftKings
Press releaseJul 23, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines - ZTS
Press releaseJul 22, 12:00 PM ETBusiness Wire
Deadline Soon: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Press releaseJul 22, 7:30 AM ETBusiness Wire
Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
Press releaseJul 21, 10:07 AM ETGlobe Newswire
Portnoy Law Firm Announces Class Action on Behalf of Zoetis, Inc. Investors
Press releaseJul 21, 10:05 AM ETPRNewswire
ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
Press releaseJul 21, 10:03 AM ETPRNewswire
ZTS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages ZTS Investors with Losses to Contact the Firm
Press releaseJul 20, 5:50 PM ETGlobe Newswire
ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th: Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline
Press releaseJul 20, 4:15 PM ETPRNewswire
ZTS Deadline: ZTS Investors with Loses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
Press releaseJul 20, 1:47 PM ETBusiness Wire
ZTS Deadline: Rosen Law Firm Urges Zoetis Inc. (NYSE: ZTS) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Press releaseJul 18, 9:40 AM ETGlobe Newswire
Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
NewsJul 17, 9:57 AM ETVandana Singh
Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia
Press releaseJul 16, 10:09 AM ETPRNewswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS
Press releaseJul 16, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines - ZTS
Press releaseJul 15, 10:00 PM ETPRNewswire
Zoetis Deadline: ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
Press releaseJul 15, 2:37 PM ETPRNewswire
Zoetis Inc. (ZTS) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact KTMC
Press releaseJul 15, 10:11 AM ETPRNewswire
Levi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTS
Press releaseJul 15, 8:30 AM ETBusiness Wire
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
Press releaseJul 14, 9:00 AM ETBusiness Wire
Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities
Press releaseJun 4, 5:33 PM ETPRNewswire
ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
Press releaseJun 4, 8:30 AM ETBusiness Wire
Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future
Press releaseJun 1, 3:09 PM ETGlobe Newswire
ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Press releaseMar 2, 7:00 AM ETBusiness Wire
Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation
NewsNov 20, 12:00 PM ET
A Look Into Zoetis Inc's Price Over Earnings
NewsMay 19, 12:00 PM ET
A Look Into Zoetis Inc's Price Over Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Zoetis Appoints Iris Knobloch to its Board of Directors

Zoetis Declares Fourth Quarter 2026 Dividend

New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

Zoetis Reports Q2 2026 Results: Full Earnings Call Transcript

Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds

Zoetis Q2 Adj. EPS $1.87 Beats $1.86 Estimate, Sales $2.468B Miss $2.502B Estimate

Zoetis Announces Second Quarter 2026 Results

Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer

Michael Burry Expands Bets Against Nvidia, Micron— and Is Now Buying Lululemon and DraftKings

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines - ZTS

Deadline Soon: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Portnoy Law Firm Announces Class Action on Behalf of Zoetis, Inc. Investors

ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

ZTS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages ZTS Investors with Losses to Contact the Firm

ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th: Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline

ZTS Deadline: ZTS Investors with Loses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit

ZTS Deadline: Rosen Law Firm Urges Zoetis Inc. (NYSE: ZTS) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines - ZTS

Zoetis Deadline: ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit

Zoetis Inc. (ZTS) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact KTMC

Levi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTS

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union

Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities

ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future

ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation

A Look Into Zoetis Inc's Price Over Earnings

A Look Into Zoetis Inc's Price Over Earnings